Indivior Operating Expenses 2012-2024 | INDV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Indivior operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Indivior operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$74.8B
Chugai Pharmaceutical (CHGCY)	$70.2B
Takeda Pharmaceutical (TAK)	$41.1B
Sandoz Group AG (SDZNY)	$19.6B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$17.3B
United Therapeutics (UTHR)	$16B
Neurocrine Biosciences (NBIX)	$14.5B
Summit Therapeutics (SMMT)	$14B
Shionogi (SGIOY)	$12.1B
Orion OYJ (ORINY)	$7.2B
Stevanato Group S.p.A (STVN)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Corcept Therapeutics (CORT)	$5.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.5B
Grifols, S.A (GRFS)	$5B
Ionis Pharmaceuticals (IONS)	$5B
Crinetics Pharmaceuticals (CRNX)	$3.5B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Recursion Pharmaceuticals (RXRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.2B
Soleno Therapeutics (SLNO)	$2B
Centessa Pharmaceuticals (CNTA)	$2B
Hypermarcas (HYPMY)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Evotec AG (EVO)	$1.5B
Dyne Therapeutics (DYN)	$1.4B
Xencor (XNCR)	$1.3B
Guardian Pharmacy Services (GRDN)	$1.3B